Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Argatroban dose-ranging study versus unfractionated heparin during elective PCI
2004-001674-80Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of argatroban in coronary arteriosclerosis and unstable angina (4 arms), sponsored by Mitsubishi Tanabe Pharma. Primary endpoints: Triple composite at Day 30, Quadruple composite at Day 30 and in-hospital bleeding and 5 more. Started Apr 2005; status: completed.
02
Drugs
argatroban
03
Conditions
coronary arteriosclerosisunstable angina
Beyond the preview
Go deeper on 2004-001674-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001674-80.